Dr. Thomas R. Parr Jr., Ph.D. serves as Chief Scientific Officer of the Company. He has more than 30 years of drug discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining Spero, from 2012 to 2014, Dr. Parr was the Chief Scientific Officer at Fedora Pharmaceuticals, Inc. where the company moved novel diazabicyclooctane beta-lactramase inhibitors toward development partnerships. Prior to Fedora, he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. Dr. Parr earned his Ph.D. from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.
As the Chief Scientific Officer of Spero Therapeutics Inc, the total compensation of Thomas Parr at Spero Therapeutics Inc is $450,893. There are 6 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.
Thomas Parr is 66, he's been the Chief Scientific Officer of Spero Therapeutics Inc since 2014. There are 4 older and 15 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.
Thomas's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela oraz Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Spero Therapeutics Inc executives and other stock owners filed with the SEC include: